Matsukawa Y, et al. - A sum of 120 individuals were studied to estimate the efficiency of fesoterodine plus silodosin vs mirabegron plus silodosin for benign prostatic hyperplasia cases complicated by an overactive bladder (OAB). Researchers observed greater improvements in the OAB symptom score (OABSS)-total, International Prostate Symptom Score (IPSS)-QOL, and OABSS-urgency score at 12 weeks among fesoterodine group. They noticed greater improvements in the detrusor overactivity alleviation rate with fesoterodine administration. An increase in post-void residual urine by 16 mL was recorded in the fesoterodine group. Overall, they recommended add-on therapy of fesoterodine to silodosin, more efficient for improving OAB symptoms and storage functions, without deteriorating voiding symptoms or functions.